Sure. It's a good question. There's definite interest. As I have said in the past, there were two things that I think were limiting on our ability to actually get a follow-on biologics partnership going the way we had hoped to get it going. And one was the approval of enoxaparin, but the FDA actually used our technology to approve products.
The second was a follow-on biologics pathway which we got last year. So, I think we are in very active and I think fruitful discussions at this point in time. I'm not going to put any timelines on when we'll get deals, but I will say we are in active discussions at this point in time and it's looking promising for us.
Given the language I bolded, I don't translate that into MNTA saying they were "close" to a deal.
Market Data 
Markets 
AI
